- Product: Imuno identifies new ‘targets’, which only occur on tumors, and which act as recognition points for antibodies.
- Sector: Life Sciences & Health
- Founded: 2020
- Amount invested: € 300.000
- Status: Active
Imuno develops a new immunotherapy against cancer.
Imuno focuses on tumor types for which few effective drugs are currently available. Immunotherapy, unlike chemotherapy, does not target the cancer cells directly, but stimulates the immune system to clear the cancer. Imuno identifies new ‘targets’ which only occur on tumors, and which function as a recognition point for antibodies. With better and more targets, immunotherapies become more effective. The investment of UNIIQ is mainly used for further development of their model, identification of antigens, team expansion and strengthening of the IP position.